QM · rank #4 · 2026-10-27
CDNA
NASDAQ · $3.58B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +326.52% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +29.5% |
| Profit margin Net profit margin, trailing 12 months. | +24.2% |
| Market cap (USD) Size filter: > $500M required. | $3.58B |
| Anchor (recent) Close on 2026-09-25 | $63.68 |
| Anchor (far) Close on 2025-09-26 | $14.93 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
CareDx (CDNA) sells transplant-surveillance and oncology molecular diagnostics, led by AlloSure, AlloMap and newly acquired NavDx, to help clinicians monitor graft injury and recurrence without invasive procedures.
Rationale
The screen is supported by strong 12-1 momentum, high ROE and profit margins, plus accelerating revenue and raised 2026 guidance, indicating a profitable growth re-rating rather than a pure sentiment move.
Material risks
- 1Natera’s Prospera and other molecular competitors could take share from AlloSure if they win pricing, clinical-trial adoption, or assay preference in transplant surveillance.
- 2NavDx integration and reimbursement execution could disappoint if billing, Epic connectivity, or payer economics slow the expected Q3 contribution and scale-up.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.